Peer ReviewedFDA Approved
Tesamorelin Dosing Guide
Evidence-based dosing protocols across 2 administration approaches.
Medical Disclaimer
This dosing information is for educational reference only. Dosing decisions require physician oversight. Do not self-prescribe or adjust dosing without consulting a qualified healthcare provider.
Dosing Protocols
HIV Lipodystrophy (FDA-Approved)
FDA ApprovedSubcutaneousDose Range
1.4–2 mg
Frequency
daily
Source
Egrifta FDA Label; LIPO-010 & CTR-1011 Phase III trials
Egrifta SV: 1.4 mg daily. Egrifta WR: 1.28 mg daily. 19.6% VAT reduction in trials. Effects reverse upon discontinuation.
Body Composition (Off-Label)
Off-Label ClinicSubcutaneousDose Range
1–2 mg
Frequency
daily
Duration
3-month cycles with 2-week breaks
Some providers use 2 mg several times/wk rather than daily. Inject abdomen at bedtime.
Administration
Delivery methods
Subcutaneous injection
⏳
Pending physician review — consult your provider before use.Updated 2026-04-10